Stay updated on Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.

Latest updates to the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe site’s displayed software revision changes from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check27 days agoChange DetectedA banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” across its content.SummaryDifference0.7%

- Check34 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check41 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check62 days agoChange DetectedA new revision entry v3.7.0 was added to the Record History, and the previous v3.6.6 entry was removed.SummaryDifference0.1%

- Check83 days agoChange DetectedThe history now includes a new Revision: v3.6.6 entry, replacing the previous Revision: v3.6.5. This reflects a minor metadata update to the page’s version history on ClinicalTrials.gov.SummaryDifference0.1%

Stay in the know with updates to Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.